Neuren Pharmaceuticals extends trofinetide patent to 2041

• Acadia Pharmaceuticals received a notice of allowance for a patent covering the weight-banded dosing of trofinetide.
• The Neuren share price traded lower to $20.21 following the intellectual property update.
• Neuren stated the new patent is expected to provide US market protection until March 2041.

Neuren Pharmaceuticals (ASX:NEU) announced partner Acadia Pharmaceuticals (NASDAQ:ACAD) secured a US patent allowance extending trofinetide protections.

The new patent extends exclusivity by almost five years beyond the previous use patent expiring in July 2036.

The pending patent covers the weight-banded dosing regimen for the Rett syndrome drug DAYBUE.

Neuren stated the patent is expected to issue after standard administrative steps and a paediatric exclusivity period.

The company stated the issuance is expected to prolong market protection.

Following the announcement, the Neuren Pharmaceuticals share price was down at $20.21.

The business focuses on developing orally administered therapies for serious neurological disorders with limited approved treatments.

Neuren is also advancing ercanetide for multiple neurodevelopmental disorders under US orphan drug designations.